{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-148920","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2026-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.945203+00:00","generated_at":"2026-05-15T06:45:34.348773+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"confidence":"high","headline":"Plus Therapeutics appoints Eric J. Daniels as CDO; base salary $460K, equity grant","bullets":["Daniels becomes Chief Development Officer effective April 20, 2026, reporting to CEO.","Prior role: Chief Development Officer at Kiora Pharmaceuticals (NASDAQ:KPRX) from Oct 2021 to Apr 2026.","Initial annual base salary of $460,000; target bonus of 40% of base salary.","Equity inducement: option for 20,000 shares vesting over 4 years (1-yr cliff) and 20,000 RSUs vesting over 3 years.","Severance on involuntary termination: 12 months' salary plus target bonus, plus vesting acceleration on 9 months of unvested equity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-148920","json":"https://secwatch.observer/filing/0001193125-26-148920.json","markdown":"https://secwatch.observer/filing/0001193125-26-148920.md","text":"https://secwatch.observer/filing/0001193125-26-148920.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000119312526148920/0001193125-26-148920-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000119312526148920/pstv-20260408.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:45:34.348773+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}